ypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with heterogeneous morphologic, functional, and clinical features. 1-3 Although the risk of premature death, particularly in young patients, has been repeatedly emphasized, recent studies in communitybased populations have shown that heart failure and stroke events were equally important for sudden death. 4- 13 In order to prevent adverse events, including HCM-related deaths, hospitalization for heart failure and stroke admission, it is important to find reliable prognostic markers. Plasma brain natriuretic peptide (BNP) has been established to be a useful tool to manage heart failure patients, particularly patients with systolic dysfunction. However, the usefulness of this marker for assessing and predicting the precise characterization of the clinical status of HCM is still controversial. 14- 19 Furthermore, there has been no information on the utility of troponins as prognostic markers in HCM. We have recently reported that serum cardiac troponin I (cTnI), a sensitive and specific marker of myocardial injury, was associated with maximum left ventricular (LV) wall thickness and LV dysfunction in HCM and seemed to have clinical significance different from that of BNP. 20 We hypothesized that measurements of both serum cTnI and plasma BNP might supplement each other and become more reliable prognostic markers of adverse cardiovascular events in patients with HCM. The aim of this study was to determine the usefulness of combined measurements of these biomarkers in HCM.
Methods

Subjects
Patients were diagnosed as having HCM between 1982 and
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October 2008 at Kochi Medical School. In this study, we performed clinical evaluation including measurements of both cTnI and BNP in 177 consecutive patients with HCM between October 2004 and October 2008. We excluded patients with evidence of coronary artery disease (8 patients with a history of percutaneous coronary intervention) and patients with renal failure (2 patients with serum creatinine ≥3 mg/dl). The final study population consisted of 167 patients. The diagnosis of HCM was based on echocardiographic demonstration of unexplained left ventricular hypertrophy, ie, maximum LV wall thickness ≥15 mm. Informed consent was obtained from all patients or their parents in accordance with the guidelines of the Ethics Committee on Medical Research of Kochi Medical School.
Clinical Evaluation
Evaluation of patients included medical history, clinical examination, 12-lead electrocardiography, and M-mode, 2-dimensional (2-D) and Doppler echocardiography. Maximum LV wall thickness was defined as the greatest thickness in any single segment. LV end-diastolic diameter (LVEDD) and endsystolic diameter (LVESD) were measured from M-mode and 2-D images obtained from parasternal long-axis views, and fractional shortening (%FS = (LVEDD -LVESD)/LVEDD × 100) was calculated. Global ejection fraction (EF) was determined from apical 2-and 4-chamber views. LV outflow tract gradient was calculated from continuous-wave Doppler using the simplified Bernoulli equation.
Using morphologic and hemodynamic findings assessed by echocardiography, we classified the patients into 4 groups.
(1) Dilated phase of HCM (D-HCM) was defined as LV systolic dysfunction of global EF <50%. Concomitant coronary artery disease was excluded by coronary angiography and/or myocardial scintigraphy. HCM without LV systolic dysfunction included: (2) HCM with obstruction: presence of basal LV outflow tract obstruction (gradient ≥30 mmHg at rest), (3) HCM without obstruction, and (4) apical HCM: HCM without obstruction and with hypertrophy (≥15 mm) confined to the LV apex below the papillary muscle level.
For survival analysis, 3 modes of HCM-related death were 
Measurements of cTnI and BNP
Peripheral blood samples were collected for measurements of serum cTnI and plasma BNP at the time of clinical evaluation between October 2004 and October 2008. Serum cTnI was measured by a BECKMAN COULTER Unicel DxI 800 Access Immunoassay System in accordance with the manual of the manufacturer. The normal range is less than or equal to 0.03 ng/ml (97.5 percentile). Plasma BNP was measured using a highly sensitive immunoradiometric assay (Shionogi, Osaka, Japan) or enzyme immunoassay (TOSOH, Tokyo, Japan).
Statistical Analysis
All data are expressed as mean ± SD (range) or frequency (percentage). Differences in continuous variables were assessed using Student's t-test. Pearson's chi-square test was used for comparisons between non-continuous variables, and Fisher's exact test was used when expected frequency was lower than 5. Survival estimates were calculated by the Kaplan -Meier method, and the log rank test was used for comparison. The values of cTnI and BNP in cardiovascular events were analyzed through the use of a univariate Cox regression model; these results were presented as hazard ratios. The multivariate Cox proportional hazards model was used to analyze the relationships between cardiovascular events and prognostic parameters. Statistical significance was defined by P≤0.05. Statistical analysis was performed using SPSS version 14.0J (SPSS Inc, Chicago, IL, USA).
Results
Patient Population
Clinical characteristics of the patients in the present study are summarized in Table 1 . The patients were aged from 9 to 88 years (mean age, 61±16 years) and 103 (62%) of the patients were males. Of the 167 patients, 158 (95%) were asymptomatic or mildly symptomatic (New York Heart Association (NYHA) functional class I or II). Maximum LV wall thickness was 20.2±3.9 mm (range, 12 to 33 mm), and 42 patients (25%) had documentation of paroxysmal or chronic atrial fibrillation. There were 10 patients in the D-HCM group, Medical treatment of the patients is also summarized in Table 1 . Beta-blockers were used in 74 patients (44%) and calcium antagonists were prescribed in 46 patients (28%). Thirty-one patients were given diuretics. Anti-arrhythmic medicines were administered in 29 patients (17%): 16 patients received the class Ia anti-arrhythmic drug dysopyramide or cibenzoline for relieving outflow tract obstruction and 3 patients received amiodarone for ventricular tachycardia, and mexiletine and pilsicainide were prescribed in some patients.
cTnI and Baseline Patient Characteristics
Serum cTnI ranged from 0.01 to 0.83 ng/ml (mean, 0.070± 0.100 ng/ml; median, 0.04 ng/ml) ( Table 1) . We divided the patients into 2 groups by median values of cTnI: low cTnI group (cTnI <0.04 ng/ml) and high cTnI group (cTnI ≥0.04 ng/ml). There was no difference in ages between the 2 groups ( Table 1 ). The percentage of male patients in the high cTnI group was higher than that in the low cTnI group. More patients with high cTnI values experienced significant dyspnea (NYHA class III). There were more D-HCM patients and fewer patients with apical HCM in the high cTnI group. Results of echocardiography showed that left atrial diameter was larger and interventricular septal wall, posterior wall, and maximum LV wall thicknesses were greater in patients with high cTnI levels than in patients with low cTnI levels.
BNP and Baseline Patient Characteristics
BNP ranged from 4 to 1,920 pg/ml (mean, 282.9±288.6 pg/ml; median, 200 pg/ml) ( Table 1 ). The patients were divided into 2 groups by median values of BNP: low BNP group (BNP <200 pg/ml) and high BNP group (BNP ≥200 pg/ml). As shown in Table 2 , similar to the results for subgroups established by cTnI values, there were fewer patients with NYHA functional class I and fewer patients with apical HCM in the high BNP group, and left atrial size and maximum LV wall thickness were greater in patients with high BNP values than in patients with low BNP values. However, different from the results for subgroups established by cTnI values, the percentage of female patients and the percentage of patients with HCM with obstruction were higher in the high BNP group. The prevalence of atrial fibrillation was significantly higher in patients with high BNP values. There was no difference in serum cTnI levels between the 2 groups.
Adverse Cardiovascular Events
The mean follow-up period of the patient cohort was 38.5± 17.6 months, and 20 patients suffered from cardiovascular events ( Table 3) . Cardiovascular deaths occurred in 6 of those 20 patients: sudden death in 1 patient, heart failure death in 3 patients and embolic stroke death in 2 patients. The 2 patients in whom stroke death occurred had heart failure admission (1 with D-HCM and the other with severe diastolic heart failure) before embolic events. Morbid events occurred in 14 other patients: hospitalization for heart failure in 8 patients, embolic stroke admission in 5 patients and 1 with successful recovery from spontaneous ventricular tachycardia associated with hemodynamic instability. Of the 7 patients in whom stroke death occurred or who had stroke admission, 6 patients had chronic atrial fibrillation and received warfarin for prevention of embolism, and the remaining one patient had sinus rhythm with no detectable paroxysmal atrial fibrillation.
Measurements of cTnI and BNP and Adverse Outcomes
Patients with high cTnI values had significantly more frequent cardiovascular events including HCM-related deaths and major morbid events than did patients with low cTnI values ( Figure 1A) . Similarly, there were more frequent cardiovascular events in the high BNP group than in the low BNP group (Figure 1B) .
When groups were allocated according to both cTnI and BNP measurements, serum cTnI used in conjunction with BNP further improved the prognostic value. Figure 1C shows the Kaplan -Meier curves for cardiaovascular events. The clinical course was significantly worse in the group of both high Figure 2 . Whole hypertrophic cardiomyopathy patients' cohort. Cardiovascular event rate stratified by cardiac troponin I (cTnI) and brain natriuretic peptide (BNP). Low cTnI; cTnI <0.04 ng/ml, high cTnI; ≥0.04 ng/ml, low BNP <200 pg/ml, high BNP ≥200 pg/ml. CI, confidence interval. KUBO T et al.
cTnI and BNP. Cardiovascular death occurred in 6 patients in the high cTnI and high BNP group. However, there was no cardiovascular death in other patient groups. Figure 2 shows the rates of cardiovascular events in the 4 subgroups established by combinations of cTnI and BNP values. The incidences of cardiovascular events were 0.8, 1.3, 1.8 and 9.0 per 100 person-years in the low cTnI and low BNP group, low cTnI and high BNP group, high cTnI and low BNP group, and high cTnI and high BNP group, respectively. Patients with both high cTnI and BNP values had an 11.7-fold increased risk of cardiovascular events compared with those with both low cTnI and BNP values.
To determine the usefulness of combined measurements of these biomarkers in patients with preserved systolic function, we excluded 10 patients with D-HCM, characterized by LV systolic dysfunction, and analyzed the data for clinical events, because D-HCM is now recognized to have a poor prognosis. In the present study, there were 7 clinical events in those 10 patients with D-HCM: heart failure death in 2 patients, embolic stroke death in 1 patient and hospitalization for heart failure in 4 patients. Even in patients with preserved systolic function, the clinical course was significantly worse in the group of both high cTnI and BNP (Figures 3A,B) . Cardiovascular events (total of 13 events) including hypertrophic cardiomyopathy-related deaths, hospitalization for heart failure, embolic stroke admission and spontaneous ventricular tachycardia associated with hemodynamic instability. (B) Cardiovascular event rate stratified by cTnI and BNP. Low cTnI; cTnI <0.04 ng/ml, high cTnI; ≥0.04 ng/ml, low BNP <200 pg/ml, high BNP ≥200 pg/ml. CI, confidence interval. Biomarkers in HCM
Predictors of Cardiovascular Events
By multivariate Cox proportional hazards model analysis including gender, age (age at evaluation ≥65 years old), presence of atrial fibrillation, LV outflow tract obstruction and marked hypertrophy (maximum LV wall thickness ≥30 mm), and combined measurements of biomarkers (both high cTnI and BNP), the presence of atrial fibrillation (P=0.007) and both high cTnI and BNP (P=0.028) were significant predictors of cardiovascular events.
Discussion
HCM is a heterogeneous myocardial disorder with a broad spectrum of clinical presentations and morphologic features. 1-3 The natural history of HCM varies from an asymptomatic and benign clinical course to sudden premature death. Recent observations in community-based cohorts have shown that not only sudden death but also heart failure and stroke related to HCM were important adverse events. 7-13 Several risk factors for sudden cardiac death, including degree of LV hypertrophy, family history of sudden death and unexplained syncope, have been established. 1-6 In addition, advanced age and the presence of atrial fibrillation, basal outflow obstruction and congestive symptoms were found to be clinically important predictors of HCM mortality or stroke. 8,12,21,22 However, it is still difficult to predict the precise characterization of the clinical status because the positive predictive values of these clinical markers for adverse events were not high and this difficulty in prediction was thought to be due to markedly diverse heterogeneity of clinical phenotypes in HCM. However, although biomarkers such as serum troponins and plasma BNP have become clinically important tools as diagnostic and prognostic markers for ischemic heart disease and heart failure, particularly LV systolic dysfunction, the usefulness of these biomarkers for evaluation and risk stratification of patients with HCM is less certain. 14-19,23- 25 In this study, we therefore investigated the usefulness of these biomarkers, cTnI (a sensitive and specific marker of myocardial injury) and BNP reflecting cardiac load, for predicting adverse outcomes in patients with HCM. To the best of our knowledge, this is the first report showing that cTnI used in conjunction with BNP further improved the prognostic value in patients with HCM.
In the present study, we divided the patients into 2 groups by cTnI values and 2 groups by BNP values. Both of the cutoff values, 0.04 ng/ml for cTnI and 200 pg/ml for BNP, were median values from the present patient cohort. Because the normal range is less than or equal to 0.03 ng/ml (97.5 percentile) in our system for measuring cTnI, the cTnI value of 0.04 ng/ml is considered to be reasonable. Horwich et al screened patients with heart failure for detectable cTnI levels and found that patients with detectable cTnI levels (≥0.04 ng/ml in their study) had impaired hemodynamics, progressive LV systolic dysfunction, and increased mortality rates. 24 For BNP values, Maron et al reported that BNP was useful in assessment of the symptomatic state in HCM and that BNP ≥200 pg/ml was the most reliable predictor of heart failure symptoms. 15 We therefore divided patients into a BNP <200 pg/ml group and a BNP ≥200 pg/ml group.
In the baseline clinical characteristics, there were less patients with NYHA functional class I and less patients with apical HCM in the high cTnI group and the high BNP group. Larger left atrial size and greater maximum LV wall thickness were observed both in the high cTnI group and the high BNP group. These results indicated that high cTnI or BNP is associated with findings supporting clinical deterioration. However, the percentage of male patients was higher in the high cTnI group, whereas the percentage of female patients was higher in the high BNP group. Furthermore, although D-HCM, characterized by LV systolic dysfunction and cavity dilatation, was significantly more frequent in the high cTnI group, HCM with obstruction, not D-HCM, was significantly more frequent in patients with high BNP values. We have recently reported the clinical significance of serum cTnI and plasma BNP: cTnI was significantly related to maximum LV wall thickness and BNP was significantly higher with respect to progressive severity of heart failure symptoms, as judged by NYHA functional class. 20 Although the mechanisms of myocyte injury and release of cTnI in HCM remain unresolved, we speculate that it might be caused by relative myocardial ischemia resulting from an inbalance between inappropriate hypertrophy of the myocardium and insufficient coronary arterial supply. However, BNP is likely to reflect cardiac load, but cTnI seems to be a less sensitive marker of LV filling pressure. The results indicate that the clinical significance of cTnI seemed to be different from that of BNP and that the combination of serum cTnI and plasma BNP is a more reliable prognostic marker.
During the follow-up period of 38.5±17.6 months, HCMrelated deaths occurred in 6 patients and 14 other patients experienced major morbid events including hospitalization for heart failure, embolic stroke admission, and spontaneous sustained ventricular tachycardia. The annual mortality rate in the present study was 1.1%, which is in accordance with previously reported data obtained from community-based cohorts for HCM. 7- 12 The patients were divided into groups according to values of cTnI and BNP. Patients with high cTnI values had significantly more frequent cardiovascular events than did those with low cTnI values, and these adverse events were also observed more frequently in the high BNP group than in the low BNP group (Figures 1A,B) . There has been no information on the utility of troponins as prognostic markers in HCM. For BNP, Mutlu et al reported that plasma levels of N-terminal pro-BNP (NT-pro-BNP) seemed to be a reliable parameter to identify patients at risk for clinical events. 17 They found that patients with baseline plasma NT-pro-BNP levels ≥1,500 pg/ml had increased risk for clinical deterioration including cardiovascular death and hospitalization for worsening heart failure symptoms in the following 2 years. However, Takeuchi et al reported that plasma BNP levels did not always reflect the severity of heart failure in HCM patients without obstruction. 16 Although our results also showed that patients with high BNP values are likely to have more clinical events than are those with low BNP values, the positive predictive value of this marker for adverse events was low, as are other established risk factors in HCM. However, combined measurements of cTnI and BNP improved the prognostic value significantly; HCM patients with a markedly increased risk of cardiovascular events (11.7-fold increase) were identified by the combination of both high cTnI and BNP. Furthermore, even in patients with preserved LV systolic function (non-D-HCM), the group of both high cTnI and BNP had more frequent cardiovascular events.
Cox proportional hazard analysis revealed that the presence of atrial fibrillation and both high cTnI and BNP were significant predictors of cardiovascular events. Atrial fibrillation has been recognized to be an important factor related to clinical deterioration in HCM patients. 12, 21 In our cohort, the prognostic power of these 2 biomarkers appeared to be KUBO T et al.
high and, at least, to be additive to other predictors of adverse events, particularly heart failure and stroke, in HCM. Patients with both high cTnI and BNP values might benefit from more aggressive treatment strategies such as more strict medications, including anticoagulation therapy, or implantation of cardioverter defibrillator devices for ventricular arrhythmias or bi-ventricular pacing for heart failure.
Our study cohort differs from tertiary center cohorts in which referral patterns are skewed toward patients perceived to be at high risk. The present study was a community-based cohort and included less high-risk patients than those in major referral centers. That is, prevalence of HCM with obstruction was low and only one patient suffered from sudden death during the follow-up period in our study. Therefore, it remains unclear whether combined measurements of these biomarkers (cTnI and BNP) in HCM patients with high risk, particularly for sudden death, are useful.
In conclusion, serum cTnI and plasma BNP seem to be useful parameters for identifying HCM patients at risk for clinical deterioration including HCM-related death, hospitalization for heart failure and stroke admission. Combined measurements of these biomarkers are more reliable predictors of increased cardiovascular events and might be useful as novel and additive monitoring parameters in this patient population.
